(Q39684120)

14 September 2017

title

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies (English)

1 reference

14 September 2017

1 reference

1 reference

1 reference

X Ye

1

1 reference

14 September 2017

Y Li

2

1 reference

14 September 2017

S Stawicki

3

1 reference

14 September 2017

S Couto

4

1 reference

14 September 2017

J Eastham-Anderson

5

1 reference

14 September 2017

D Kallop

6

1 reference

14 September 2017

R Weimer

7

1 reference

14 September 2017

Y Wu

8

1 reference

14 September 2017

L Pei

9

1 reference

14 September 2017

language of work or name

English

0 references

publication date

5 July 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

29

1 reference

14 September 2017

issue

38

1 reference

14 September 2017

page(s)

5254-5264

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2010.268

14 September 2017

exact match

0 references

cites work

Automated selection of DAB-labeled tissue for immunohistochemical quantification.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Inflammation and cancer: back to Virchow?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Expression of the proto-oncogene Axl in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

31 March 2020

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Receptor tyrosine kinases expressed in metastatic colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Multiple roles for the receptor tyrosine kinase axl in tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Tumour-educated macrophages promote tumour progression and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Expression of axl in lung adenocarcinoma and correlation with tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Coexpression of Gas6/Axl in human ovarian cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Erlotinib in lung cancer - molecular and clinical predictors of outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

AXL is a potential target for therapeutic intervention in breast cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.268

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.268

1 reference

14 September 2017

1 reference